Caffeine citrate is now available in Russia
Mirpharm has registered Caffeine Citrate (INN) for the treatment of primary apnea (breathing arrest) in preterm infants.
Moscow, March 2022
Caffeine citrate (INN), actively used by neonatologists all over the world, has become available to Russian doctors.
Launched by Mirpharm, Caffeine Citrate is specifically designed for neonatologists to combat apnea of prematurity. The drug is known in the world, but for the first time presented in Russia.
Its use allows for a much earlier cessation of assisted ventilation, a reduction in the incidence of BPD, and a significant improvement in survival without neurodevelopmental impairment.
Mirpharm is an international group of companies with its own R&D centers and production facilities in Russia and the European Union.